Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.

Schütze K, Petry K, Hambach J, Schuster N, Fumey W, Schriewer L, Röckendorf J, Menzel S, Albrecht B, Haag F, Stortelers C, Bannas P, Koch-Nolte F.

Front Immunol. 2018 Nov 19;9:2553. doi: 10.3389/fimmu.2018.02553. eCollection 2018.

2.

Anti-TTR Nanobodies Allow the Identification of TTR Neuritogenic Epitope Associated with TTR-Megalin Neurotrophic Activities.

Gomes JR, Sárkány Z, Teixeira A, Nogueira R, Cabrito I, Soares H, Wittelsberger A, Stortelers C, Macedo-Ribeiro S, Vanlandschoot P, Saraiva MJ.

ACS Chem Neurosci. 2019 Jan 16;10(1):704-715. doi: 10.1021/acschemneuro.8b00502. Epub 2018 Oct 23.

PMID:
30346709
3.

Modulating ion channel function with antibodies and nanobodies.

Stortelers C, Pinto-Espinoza C, Van Hoorick D, Koch-Nolte F.

Curr Opin Immunol. 2018 Jun;52:18-26. doi: 10.1016/j.coi.2018.02.003. Epub 2018 Mar 23. Review.

PMID:
29579624
4.

Delivery of an anti-transthyretin Nanobody to the brain through intranasal administration reveals transthyretin expression and secretion by motor neurons.

Gomes JR, Cabrito I, Soares HR, Costelha S, Teixeira A, Wittelsberger A, Stortelers C, Vanlandschoot P, Saraiva MJ.

J Neurochem. 2018 Jun;145(5):393-408. doi: 10.1111/jnc.14332. Epub 2018 May 9.

5.

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo.

Fumey W, Koenigsdorf J, Kunick V, Menzel S, Schütze K, Unger M, Schriewer L, Haag F, Adam G, Oberle A, Binder M, Fliegert R, Guse A, Zhao YJ, Cheung Lee H, Malavasi F, Goldbaum F, van Hegelsom R, Stortelers C, Bannas P, Koch-Nolte F.

Sci Rep. 2017 Oct 30;7(1):14289. doi: 10.1038/s41598-017-14112-6.

6.

Large Diversity of Functional Nanobodies from a Camelid Immune Library Revealed by an Alternative Analysis of Next-Generation Sequencing Data.

Deschaght P, Vintém AP, Logghe M, Conde M, Felix D, Mensink R, Gonçalves J, Audiens J, Bruynooghe Y, Figueiredo R, Ramos D, Tanghe R, Teixeira D, Van de Ven L, Stortelers C, Dombrecht B.

Front Immunol. 2017 Apr 10;8:420. doi: 10.3389/fimmu.2017.00420. eCollection 2017.

7.

Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation.

Danquah W, Meyer-Schwesinger C, Rissiek B, Pinto C, Serracant-Prat A, Amadi M, Iacenda D, Knop JH, Hammel A, Bergmann P, Schwarz N, Assunção J, Rotthier W, Haag F, Tolosa E, Bannas P, Boué-Grabot E, Magnus T, Laeremans T, Stortelers C, Koch-Nolte F.

Sci Transl Med. 2016 Nov 23;8(366):366ra162.

PMID:
27881823
8.

Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection.

Palomo C, Mas V, Detalle L, Depla E, Cano O, Vázquez M, Stortelers C, Melero JA.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6498-6509. doi: 10.1128/AAC.00842-16. Print 2016 Nov.

9.

Post-exposure Treatment with Anti-rabies VHH and Vaccine Significantly Improves Protection of Mice from Lethal Rabies Infection.

Terryn S, Francart A, Rommelaere H, Stortelers C, Van Gucht S.

PLoS Negl Trop Dis. 2016 Aug 2;10(8):e0004902. doi: 10.1371/journal.pntd.0004902. eCollection 2016 Aug.

10.

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.

Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E.

Antimicrob Agents Chemother. 2015 Oct 5;60(1):6-13. doi: 10.1128/AAC.01802-15. Print 2016 Jan.

11.

Protective effect of different anti-rabies virus VHH constructs against rabies disease in mice.

Terryn S, Francart A, Lamoral S, Hultberg A, Rommelaere H, Wittelsberger A, Callewaert F, Stohr T, Meerschaert K, Ottevaere I, Stortelers C, Vanlandschoot P, Kalai M, Van Gucht S.

PLoS One. 2014 Oct 27;9(10):e109367. doi: 10.1371/journal.pone.0109367. eCollection 2014.

12.

Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.

Maussang D, Mujić-Delić A, Descamps FJ, Stortelers C, Vanlandschoot P, Stigter-van Walsum M, Vischer HF, van Roy M, Vosjan M, Gonzalez-Pajuelo M, van Dongen GA, Merchiers P, van Rompaey P, Smit MJ.

J Biol Chem. 2013 Oct 11;288(41):29562-72. doi: 10.1074/jbc.M113.498436. Epub 2013 Aug 26.

13.

Nanobodies®: new ammunition to battle viruses.

Vanlandschoot P, Stortelers C, Beirnaert E, Ibañez LI, Schepens B, Depla E, Saelens X.

Antiviral Res. 2011 Dec;92(3):389-407. doi: 10.1016/j.antiviral.2011.09.002. Epub 2011 Sep 10. Review.

PMID:
21939690
14.

In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation.

Taghavi P, Verhoeven E, Jacobs JJ, Lambooij JP, Stortelers C, Tanger E, Moolenaar WH, van Lohuizen M.

Oncogene. 2008 Nov 20;27(54):6806-16. doi: 10.1038/onc.2008.294. Epub 2008 Sep 1.

PMID:
18762810
15.

Multiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling.

Stortelers C, Kerkhoven R, Moolenaar WH.

BMC Genomics. 2008 Aug 14;9:387. doi: 10.1186/1471-2164-9-387.

16.

Upregulation of cytokine expression in fibroblasts exposed to loxosceles sphingomyelinase D: what is the trigger?

van Meeteren LA, Stortelers C, Moolenaar WH.

J Invest Dermatol. 2007 May;127(5):1266-7; author reply 1267-8. Epub 2007 Mar 8. No abstract available.

17.

Negative constraints underlie the ErbB specificity of epidermal growth factor-like ligands.

van der Woning SP, van Rotterdam W, Nabuurs SB, Venselaar H, Jacobs-Oomen S, Wingens M, Vriend G, Stortelers C, van Zoelen EJ.

J Biol Chem. 2006 Dec 29;281(52):40033-40. Epub 2006 Oct 10.

18.

Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.

van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradère JP, Pettit TR, Wakelam MJ, Saulnier-Blache JS, Mummery CL, Moolenaar WH, Jonkers J.

Mol Cell Biol. 2006 Jul;26(13):5015-22.

19.

Epidermal growth factor mutant with wild-type affinity for both ErbB1 and ErbB3.

Wingens M, Jacobs-Oomen S, van der Woning SP, Stortelers C, van Zoelen EJ.

Biochemistry. 2006 Apr 11;45(14):4703-10.

PMID:
16584205
20.

Structural analysis of an epidermal growth factor/transforming growth factor-alpha chimera with unique ErbB binding specificity.

Wingens M, Walma T, van Ingen H, Stortelers C, van Leeuwen JE, van Zoelen EJ, Vuister GW.

J Biol Chem. 2003 Oct 3;278(40):39114-23. Epub 2003 Jul 16.

21.

Selective formation of ErbB-2/ErbB-3 heterodimers depends on the ErbB-3 affinity of epidermal growth factor-like ligands.

Stortelers C, van der Woning SP, Jacobs-Oomen S, Wingens M, van Zoelen EJ.

J Biol Chem. 2003 Apr 4;278(14):12055-63. Epub 2003 Jan 28.

22.

Role of the N-terminus of epidermal growth factor in ErbB-2/ErbB-3 binding studied by phage display.

Stortelers C, Souriau C, van Liempt E, van de Poll ML, van Zoelen EJ.

Biochemistry. 2002 Jul 9;41(27):8732-41.

PMID:
12093292
23.

Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2/ErbB-3 heterodimers.

Stortelers C, van De Poll ML, Lenferink AE, Gadellaa MM, van Zoelen C, van Zoelen EJ.

Biochemistry. 2002 Apr 2;41(13):4292-301.

PMID:
11914075
24.

Non-linear antigenic regions in epidermal growth factor (EGF) and transforming growth factor alpha (TGF alpha) studied by EGF-TGF alpha chimaeras.

van de Poll ML, van Rotterdam W, Gadellaa MM, Stortelers C, van Vugt MJ, van Zoelen EJ.

Biochem J. 2000 Jul 1;349(Pt 1):267-74.

25.

The EGF domain: requirements for binding to receptors of the ErbB family.

Van Zoelen EJ, Stortelers C, Lenferink AE, Van de Poll ML.

Vitam Horm. 2000;59:99-131. Review.

PMID:
10714238
26.

Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97.

Hamann J, Stortelers C, Kiss-Toth E, Vogel B, Eichler W, van Lier RA.

Eur J Immunol. 1998 May;28(5):1701-7.

Supplemental Content

Loading ...
Support Center